Shamir R Mehta1, Jia Wang1, David A Wood2, John A Spertus3, David J Cohen4,5, Roxana Mehran6, Robert F Storey7, Philippe Gabriel Steg8, Natalia Pinilla-Echeverri1, Tej Sheth1, Kevin R Bainey9, Sripal Bangalore10, Warren J Cantor11, David P Faxon12, Laurent J Feldman8, Sanjit S Jolly1, Vijay Kunadian13, Shahar Lavi14, Jose Lopez-Sendon15, Mina Madan16, Raul Moreno15, Sunil V Rao17, Josep Rodés-Cabau18, Goran Stankovic19, Shrikant I Bangdiwala1, John A Cairns2. 1. Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. 2. University of British Columbia, Vancouver, British Columbia, Canada. 3. Saint Luke's Mid America Heart Institute and the University of Missouri-Kansas City, Kansas City. 4. Cardiovascular Research Foundation, New York, New York. 5. St Francis Hospital, Roslyn, New York. 6. The Zena A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 7. Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom. 8. Université Paris Cité, INSERM U-1148, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France and FACT (French Alliance for Cardiovascular Trials), Paris, France. 9. University of Alberta, Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada. 10. New York University Grossman School of Medicine, New York. 11. Southlake Regional Health Centre, University of Toronto, Toronto, Ontario, Canada. 12. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 13. Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University and Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom. 14. Western University, London Health Sciences Centre, London, Ontario, Canada. 15. Hospital Universitario La Paz, UAM, IdiPaz Research Institute, Madrid, Spain. 16. Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. 17. NYU Langone Health System, New York. 18. Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec City, Quebec, Canada. 19. Serbia to Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Abstract
Importance: In patients with multivessel coronary artery disease (CAD) presenting with ST-segment elevation myocardial infarction (STEMI), complete revascularization reduces major cardiovascular events compared with culprit lesion-only percutaneous coronary intervention (PCI). Whether complete revascularization also improves angina-related health status is unknown. Objective: To determine whether complete revascularization improves angina status in patients with STEMI and multivessel CAD. Design, Setting, and Participants: This secondary analysis of a randomized, multinational, open label trial of patient-reported outcomes took place in 140 primary PCI centers in 31 countries. Patients presenting with STEMI and multivessel CAD were randomized between February 1, 2013, and March 6, 2017. Analysis took place between July 2021 and December 2021. Interventions: Following PCI of the culprit lesion, patients with STEMI and multivessel CAD were randomized to receive either complete revascularization with additional PCI of angiographically significant nonculprit lesions or to no further revascularization. Main Outcomes and Measures: Seattle Angina Questionnaire Angina Frequency (SAQ-AF) score (range, 0 [daily angina] to 100 [no angina]) and the proportion of angina-free individuals by study end. Results: Of 4041 patients, 2016 were randomized to complete revascularization and 2025 to culprit lesion-only PCI. The mean (SD) age of patients was 62 (10.7) years, and 3225 (80%) were male. The mean (SD) SAQ-AF score increased from 87.1 (17.8) points at baseline to 97.1 (9.7) points at a median follow-up of 3 years in the complete revascularization group (score change, 9.9 [95% CI, 9.0-10.8]; P < .001) compared with an increase of 87.2 (18.4) to 96.3 (10.9) points (score change, 8.9 [95% CI, 8.0-9.8]; P < .001) in the culprit lesion-only group (between-group difference, 0.97 points [95% CI, 0.27-1.67]; P = .006). Overall, 1457 patients (87.5%) were free of angina (SAQ-AF score, 100) in the complete revascularization group compared with 1376 patients (84.3%) in the culprit lesion-only group (absolute difference, 3.2% [95% CI, 0.7%-5.7%]; P = .01). This benefit was observed mainly in patients with nonculprit lesion stenosis severity of 80% or more (absolute difference, 4.7%; interaction P = .02). Conclusions and Relevance: In patients with STEMI and multivessel CAD, complete revascularization resulted in a slightly greater proportion of patients being angina-free compared with a culprit lesion-only strategy. This modest incremental improvement in health status is in addition to the established benefit of complete revascularization in reducing cardiovascular events.
Importance: In patients with multivessel coronary artery disease (CAD) presenting with ST-segment elevation myocardial infarction (STEMI), complete revascularization reduces major cardiovascular events compared with culprit lesion-only percutaneous coronary intervention (PCI). Whether complete revascularization also improves angina-related health status is unknown. Objective: To determine whether complete revascularization improves angina status in patients with STEMI and multivessel CAD. Design, Setting, and Participants: This secondary analysis of a randomized, multinational, open label trial of patient-reported outcomes took place in 140 primary PCI centers in 31 countries. Patients presenting with STEMI and multivessel CAD were randomized between February 1, 2013, and March 6, 2017. Analysis took place between July 2021 and December 2021. Interventions: Following PCI of the culprit lesion, patients with STEMI and multivessel CAD were randomized to receive either complete revascularization with additional PCI of angiographically significant nonculprit lesions or to no further revascularization. Main Outcomes and Measures: Seattle Angina Questionnaire Angina Frequency (SAQ-AF) score (range, 0 [daily angina] to 100 [no angina]) and the proportion of angina-free individuals by study end. Results: Of 4041 patients, 2016 were randomized to complete revascularization and 2025 to culprit lesion-only PCI. The mean (SD) age of patients was 62 (10.7) years, and 3225 (80%) were male. The mean (SD) SAQ-AF score increased from 87.1 (17.8) points at baseline to 97.1 (9.7) points at a median follow-up of 3 years in the complete revascularization group (score change, 9.9 [95% CI, 9.0-10.8]; P < .001) compared with an increase of 87.2 (18.4) to 96.3 (10.9) points (score change, 8.9 [95% CI, 8.0-9.8]; P < .001) in the culprit lesion-only group (between-group difference, 0.97 points [95% CI, 0.27-1.67]; P = .006). Overall, 1457 patients (87.5%) were free of angina (SAQ-AF score, 100) in the complete revascularization group compared with 1376 patients (84.3%) in the culprit lesion-only group (absolute difference, 3.2% [95% CI, 0.7%-5.7%]; P = .01). This benefit was observed mainly in patients with nonculprit lesion stenosis severity of 80% or more (absolute difference, 4.7%; interaction P = .02). Conclusions and Relevance: In patients with STEMI and multivessel CAD, complete revascularization resulted in a slightly greater proportion of patients being angina-free compared with a culprit lesion-only strategy. This modest incremental improvement in health status is in addition to the established benefit of complete revascularization in reducing cardiovascular events.
Authors: Duk-Woo Park; Robert M Clare; Phillip J Schulte; Karen S Pieper; Linda K Shaw; Robert M Califf; E Magnus Ohman; Frans Van de Werf; Sameer Hirji; Robert A Harrington; Paul W Armstrong; Christopher B Granger; Myung-Ho Jeong; Manesh R Patel Journal: JAMA Date: 2014-11-19 Impact factor: 56.272
Authors: William S Weintraub; John A Spertus; Paul Kolm; David J Maron; Zefeng Zhang; Claudine Jurkovitz; Wei Zhang; Pamela M Hartigan; Cheryl Lewis; Emir Veledar; Jim Bowen; Sandra B Dunbar; Christi Deaton; Stanley Kaufman; Robert A O'Rourke; Ron Goeree; Paul G Barnett; Koon K Teo; William E Boden; G B J Mancini Journal: N Engl J Med Date: 2008-08-14 Impact factor: 91.245
Authors: J A Spertus; J A Winder; T A Dewhurst; R A Deyo; J Prodzinski; M McDonell; S D Fihn Journal: J Am Coll Cardiol Date: 1995-02 Impact factor: 24.094
Authors: John A Spertus; Philip G Jones; David J Maron; Sean M O'Brien; Harmony R Reynolds; Yves Rosenberg; Gregg W Stone; Frank E Harrell; William E Boden; William S Weintraub; Khaula Baloch; Kreton Mavromatis; Ariel Diaz; Gilbert Gosselin; Jonathan D Newman; Stavroula Mavromichalis; Karen P Alexander; David J Cohen; Sripal Bangalore; Judith S Hochman; Daniel B Mark Journal: N Engl J Med Date: 2020-03-30 Impact factor: 91.245
Authors: David J Maron; Judith S Hochman; Harmony R Reynolds; Sripal Bangalore; Sean M O'Brien; William E Boden; Bernard R Chaitman; Roxy Senior; Jose López-Sendón; Karen P Alexander; Renato D Lopes; Leslee J Shaw; Jeffrey S Berger; Jonathan D Newman; Mandeep S Sidhu; Shaun G Goodman; Witold Ruzyllo; Gilbert Gosselin; Aldo P Maggioni; Harvey D White; Balram Bhargava; James K Min; G B John Mancini; Daniel S Berman; Michael H Picard; Raymond Y Kwong; Ziad A Ali; Daniel B Mark; John A Spertus; Mangalath N Krishnan; Ahmed Elghamaz; Nagaraja Moorthy; Whady A Hueb; Marcin Demkow; Kreton Mavromatis; Olga Bockeria; Jesus Peteiro; Todd D Miller; Hanna Szwed; Rolf Doerr; Matyas Keltai; Joseph B Selvanayagam; P Gabriel Steg; Claes Held; Shun Kohsaka; Stavroula Mavromichalis; Ruth Kirby; Neal O Jeffries; Frank E Harrell; Frank W Rockhold; Samuel Broderick; T Bruce Ferguson; David O Williams; Robert A Harrington; Gregg W Stone; Yves Rosenberg Journal: N Engl J Med Date: 2020-03-30 Impact factor: 91.245
Authors: Jae-Sik Jang; John A Spertus; Suzanne V Arnold; Ali Shafiq; Anna Grodzinsky; Timothy J Fendler; Adam C Salisbury; Fengming Tang; Edward J McNulty; J Aaron Grantham; David J Cohen; Amit P Amin Journal: J Am Coll Cardiol Date: 2015-11-10 Impact factor: 24.094
Authors: Thomas Engstrøm; Henning Kelbæk; Steffen Helqvist; Dan Eik Høfsten; Lene Kløvgaard; Lene Holmvang; Erik Jørgensen; Frants Pedersen; Kari Saunamäki; Peter Clemmensen; Ole De Backer; Jan Ravkilde; Hans-Henrik Tilsted; Anton Boel Villadsen; Jens Aarøe; Svend Eggert Jensen; Bent Raungaard; Lars Køber Journal: Lancet Date: 2015-08-15 Impact factor: 79.321
Authors: Tej Sheth; Natalia Pinilla-Echeverri; Raul Moreno; Jia Wang; David A Wood; Robert F Storey; Roxana Mehran; Kevin R Bainey; Matthias Bossard; Sripal Bangalore; Jon-David Schwalm; James L Velianou; Nicholas Valettas; Matthew Sibbald; Josep Rodés-Cabau; John Ducas; Eric A Cohen; Akshay Bagai; Stephane Rinfret; David E Newby; Laurent Feldman; Steven B Laster; Irene M Lang; Joseph D Mills; John A Cairns; Shamir R Mehta Journal: J Am Coll Cardiol Date: 2020-09-15 Impact factor: 24.094
Authors: Anthony H Gershlick; Jamal Nasir Khan; Damian J Kelly; John P Greenwood; Thiagarajah Sasikaran; Nick Curzen; Daniel J Blackman; Miles Dalby; Kathryn L Fairbrother; Winston Banya; Duolao Wang; Marcus Flather; Simon L Hetherington; Andrew D Kelion; Suneel Talwar; Mark Gunning; Roger Hall; Howard Swanton; Gerry P McCann Journal: J Am Coll Cardiol Date: 2015-03-17 Impact factor: 24.094
Authors: Homam Ibrahim; Praneet K Sharma; David J Cohen; Gregg C Fonarow; Lisa A Kaltenbach; Mark B Effron; Marjorie E Zettler; Eric D Peterson; Tracy Y Wang Journal: J Am Heart Assoc Date: 2017-10-05 Impact factor: 5.501